We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Syncona Limited | LSE:SYNC | London | Ordinary Share | GG00B8P59C08 | ORD NPV |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-1.60 | -1.31% | 120.40 | 120.00 | 120.40 | 121.60 | 120.20 | 120.20 | 440,309 | 16:35:18 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Trust,ex Ed,religious,charty | -39.79M | -56.02M | -0.0840 | -14.31 | 801.41M |
Date | Subject | Author | Discuss |
---|---|---|---|
27/2/2024 11:25 | Looking better here......... | chrisdgb | |
02/11/2023 11:52 | Autolus looking promising. | the shuffle man | |
29/9/2023 15:36 | Desperate stuff. | shep22 | |
29/9/2023 10:10 | Share buy back seems to have stopped the drop for now. | the shuffle man | |
27/9/2023 22:49 | Syncona is in serious decline because of bad management, the issue must be addressed and quickly. | shep22 | |
22/9/2023 18:56 | Another round of selling coming, management charges urgently required. | shep22 | |
21/9/2023 12:09 | I made a small amount of money out of Sync several years ago. Just having another look again given the bombed out share price All of these sort of businesses have been hard hit by the rise in interest rates producing a double whammy of increased funding costs for portfolio companies and less opportunity to get an ipo away. Having said that a point is reached when sentiment is too negative and I think we are nearing that point, having said that, as previous posters have said, the business in now under serious pressure to produce some positive news flow which goes beyond just "we have made good progress with clinical trials" | salpara111 | |
19/9/2023 19:05 | I've learned never to average down on your losers, but average up on your winners. If institutions are dumping this, the only way is down. | chc15 | |
18/9/2023 12:06 | They need some good news on some of their more mature portfolio companies to try and change this poor sentiment. Hopefully we will hear more news on Autolus soon. Trading at a big discount to NAV and holding a lot of cash. I have done the dreaded thing and averaged down. | the shuffle man | |
18/9/2023 10:31 | Yeh gotta be institutions dumping now, wonder if Blackrock have had enough. | chc15 | |
18/9/2023 09:53 | EPIC currently describes the share price :( | spectoacc | |
12/9/2023 14:02 | Can somebody please tell me how Marin Murphy is still in a job, he has destroyed shareholder value. | shep22 | |
11/9/2023 15:07 | Yes, very disappointing. At least they got £326m upfront, so the original decision to sell was a good call. The £54.5m write-off of deferred consideration is equivalent to 8.1p per share, so net asset value is now 176.5p based on the latest quarterly update, of which over 51% is in cash. Discount to asset value is now 32%, so still looking very cheap but this is poor for sentiment and to be honest they need some good news to emerge from their drug portfolio to change that. | tiger blue | |
11/9/2023 11:46 | Oh dear, not good news, I'll hold off buying here. Blackrock must be losing tons on this. | chc15 | |
06/9/2023 13:52 | Ok thx, yeh i think they will recover, checking on shareholders, Blackrock bought a huge stake in these, so we'll see. | chc15 | |
06/9/2023 13:23 | Hugely out of favour and ignored, as you will know by being the first post since your exit one in March! While I made a lot of money from this by virtue of having them from BACIT at 100p launch and exiting average 248, and by having far more of them than was sensible, I did buy 10% of the original holding back in the mid 160's, so long and wrong on those. They are far below nav and unloved but I think there will be better days ahead when the sector turns, which might be helped once we get a turn in the interest rate cycle, as higher rates have been a big headwind for the sector. | tiger blue | |
06/9/2023 12:45 | Checking back on this dog, might be tempted to nibble back in here, seems bio still out of favour. | chc15 | |
09/3/2023 13:40 | I got out of this last week, going nowere. | chc15 | |
08/3/2023 17:05 | Lets hope not. Just bought some. trading at a decent discount with lots of cash. They have a decent track record. Just need sentiment to change towards Biotechs. There must be a persistent seller around at the moment. Lets hope they are done soon. | the shuffle man | |
08/3/2023 14:12 | Not more than.......... | spectoacc | |
08/3/2023 13:05 | 3 yr lows, can this drop much further? | chc15 | |
08/2/2023 12:00 | Not a great q3, shares taking a dive again , 6% drop, may top up a bit.. | chc15 | |
26/1/2023 09:56 | Having a small nibble here, the share price is dire.. | chc15 | |
20/11/2022 21:43 | I agree that it was an ambitious statement, but not one they had to make and at this stage unlikely to move the dial much on the share price. They are however serious people who know their sector well, with excellent contacts to enable early access to good science, and it was intriguing that they made it at all. I think they have learned a lot since launch, but still delivered a portfolio IRR of 26% to date, and stepping up the number of company launches with additional recruitment should give a boost. Despite some excellent exits NASDAQ has not been a happy place for their quoted companies, hence what reads as a shift to holding privately to exit with 'like minded' investors. That's not necessarily a bad thing, as Gyroscope had the float badly handled and pulled, but despite that soon after got a nice bid from Novartis. That was their second retinal area sale and they are back in with another new retinal venture. At the end of the day I am there on the basis that anywhere below nav they look on the cheap side, and if they get somewhere close to their target I will be well rewarded. Incidentally, if my use of the compound calculator is correct, it would take a 15% compound return to get to £5 billion over the 10 years. Yes, they have the drag of the capital pool to contend with, but given the portfolio IRR they have achieved to date it's not out of the question. | tiger blue | |
20/11/2022 20:59 | So was I, so I watched the webcast and have to say that no real guidance was given beyond that the sector itself has tremendous opportunities, and that SYNC is upping its game a tad by taking on more staff. I was hoping that in Q&A at the end one of the analysts would ask the (obvious) question, but none did. They are not upping the amount they invest pa, at least for the time being, and they are intent on keeping a big cash balance - which is sensible but a big drag on returns. Of course, it could be that they are supremely confident one of their current port cos is going to go to the moon, and the beauty of bio investing is that success can bring huge value add. Hmmm... | rambutan2 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions